Angelo Ravelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2230688/publications.pdf

Version: 2024-02-01

342	23,924	9428	10955
papers	citations	76 h-index	142 g-index

358	358	358	13078
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Predictive Value of Magnetic Resonance Imaging in Patients With Juvenile Idiopathic Arthritis in Clinical Remission. Arthritis Care and Research, 2023, 75, 198-205.	1.5	6
2	EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Annals of the Rheumatic Diseases, 2023, 82, 35-47.	0.5	23
3	Response to: â€˜Comparison of MS score and HScore for the diagnosis of adult-onset Stillâ€™s disease associated macrophage activation syndromeâ€™ by Zhanget al. Annals of the Rheumatic Diseases, 2022, 81, e100-e100.	0.5	2
4	Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. Rheumatology, 2022, 61, 1621-1629.	0.9	5
5	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Stillâ€™s disease. Rheumatology, 2022, 61, 4124-4129.	0.9	16
6	Validity and reliability of four parent/patient reported outcome measures for juvenile idiopathic arthritis remote monitoring. Arthritis Care and Research, 2022, , .	1.5	2
7	Childhood multisystem inflammatory syndrome associated with COVIDâ€19 (MISâ€C): Distinct from Kawasaki disease or part of the same spectrum?. Pediatric Allergy and Immunology, 2022, 33, 102-104.	1.1	4
8	Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis. RMD Open, 2022, 8, e002042.	1.8	3
9	Cardiovascular Manifestations in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 According to Age. Children, 2022, 9, 583.	0.6	7
10	2021 ACR guideline for JIA reflects changes in practice. Nature Reviews Rheumatology, 2022, , .	3.5	0
11	Response to â€˜Application of MS score in macrophage activation syndrome patients associated with adult onset Stillâ€™s diseaseâ€™ by Wang et al. Annals of the Rheumatic Diseases, 2021, 80, e146-e146.	0.5	1
12	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.9	8
13	Comparison Between Clinical and Ultrasound Assessment of the Ankle Region in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2021, 73, 1180-1186.	1.5	13
14	Is Macrophage Activation Syndrome in Kawasaki Disease Underrecognized?. Journal of Rheumatology, 2021, 48, 162-164.	1.0	12
15	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. Journal of Rheumatology, 2021, 48, 898-906.	1.0	4
16	Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. Italian Journal of Pediatrics, 2021, 47, 16.	1.0	31
17	Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. Current Rheumatology Reports, 2021, 23, 10.	2.1	12
18	Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers. Rheumatology, 2021, 60, 5419-5423.	0.9	5

#	Article	IF	Citations
19	Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. Italian Journal of Pediatrics, 2021, 47, 24.	1.0	68
20	The controversial role of wellbeing assessment in juvenile idiopathic arthritis. Lancet Rheumatology, The, 2021, 3, e85-e86.	2.2	2
21	Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abataceptâ€"A Case Report. Journal of Pediatric Hematology/Oncology, 2021, 43, e1168-e1172.	0.3	5
22	Neutrophil Extracellular Traps in the Autoimmunity Context. Frontiers in Medicine, 2021, 8, 614829.	1.2	25
23	Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. Pediatric Rheumatology, 2021, 19, 29.	0.9	78
24	The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders. Rheumatology, 2021, , .	0.9	4
25	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. Journal of Allergy and Clinical Immunology, 2021, 147, 1217-1225.	1.5	61
26	Expanding the clinical and neuroimaging features of post-varicella arteriopathy of childhood. Journal of Neurology, 2021, 268, 4846-4865.	1.8	6
27	Multisystem Inflammatory Syndrome in Children: Unique Disease or Part of the Kawasaki Disease Spectrum?. Frontiers in Pediatrics, 2021, 9, 680813.	0.9	24
28	Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study. Lancet Rheumatology, The, 2021, 3, e507-e516.	2.2	12
29	Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis. Expert Review of Clinical Immunology, 2021, 17, 853-870.	1.3	10
30	Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. Journal of Pediatrics, 2021, 235, 196-202.	0.9	7
31	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity ScoreÂCutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2021, 73, 1966-1975.	2.9	33
32	Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD). Clinical Immunology, 2021, 231, 108837.	1.4	4
33	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2021, 32, 3020-3023.	3.0	6
34	Multifactorial Posterior Reversible Encephalopathy Syndrome in Children: Clinical, Laboratory, and Neuroimaging Findings. Journal of Pediatric Neurology, 2021, 19, 083-091.	0.0	2
35	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology, 2021, 60, 3176-3188.	0.9	9
36	Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2021, 39, 426-433.	0.4	0

#	Article	IF	Citations
37	Neonatal lupus erythematosus in dizygotic twins with anti-RNP antibodies. Clinical and Experimental Rheumatology, 2021, 39, 1446.	0.4	1
38	A prediction rule for polyarticular extension in oligoarticular-onset juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2021, 39, 913-919.	0.4	0
39	Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C: Proposal for a Severity Score. Frontiers in Pediatrics, 2021, 9, 783745.	0.9	26
40	Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2021, 39, 426-433.	0.4	2
41	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. Journal of Rheumatology, 2020, 47, 377-386.	1.0	77
42	Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. Arthritis Care and Research, 2020, 72, 265-273.	1.5	7
43	Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. Rheumatology, 2020, 59, 344-360.	0.9	36
44	The Effect of Morning Stiffness Duration on the Definition of Clinically Inactive Disease in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2020, 47, 1238-1241.	1.0	4
45	Update on Outcome Measures for Pediatric Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 163-170.	1.5	2
46	Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases. Pediatric Rheumatology, 2020, 18, 56.	0.9	6
47	Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arhritis. Arthritis Care and Research, 2020, 73, 1722-1729.	1.5	3
48	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 3505-3514.	0.9	39
49	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Research and Therapy, 2020, 22, 211.	1.6	7
50	Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. Journal of Allergy and Clinical Immunology, 2020, 146, 213-215.	1.5	115
51	Kawasaki disease or Kawasaki syndrome?. Annals of the Rheumatic Diseases, 2020, 79, 993-995.	0.5	22
52	Macrophage activation syndrome in pediatrics. Pediatric Allergy and Immunology, 2020, 31, 13-15.	1.1	9
53	On the Alert for Cytokine Storm: Immunopathology in <scp>COVID</scp>â€19. Arthritis and Rheumatology, 2020, 72, 1059-1063.	2.9	562
54	Medicine and humanism in the time of COVID-19. Ethical choices. Acta Biomedica, 2020, 91, e2020167.	0.2	1

#	Article	IF	Citations
55	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1357-1362.	0.5	74
56	Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Research and Therapy, 2019, 21, 168.	1.6	37
57	A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. Pediatric Rheumatology, 2019, 17, 50.	0.9	5
58	Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. ACR Open Rheumatology, 2019, 1, 345-349.	0.9	47
59	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology, 2019, 58, 1196-1205.	0.9	10
60	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	0.9	15
61	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2019, 71, 579-590.	1.5	15
62	Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2019, 46, 416-421.	1.0	41
63	Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. Journal of Clinical Immunology, 2019, 39, 476-485.	2.0	85
64	The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. Pediatric Rheumatology, 2019, 17, 24.	0.9	14
65	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	2.7	120
66	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. Journal of Rheumatology, 2019, 46, 1006-1013.	1.0	34
67	Dr. Tibaldi, et al reply. Journal of Rheumatology, 2019, 46, 1424-1424.	1.0	1
68	THU0515â€...PAIN IS THE MAIN DETERMINANT OF WELL-BEING IN OLIGO- AND POLYARTICULAR JIA: EVIDENCE FROM THE PHARMACHILD REGISTRY. , 2019, , .		0
69	Fostering the application of the MS score in systemic juvenile idiopathic arthritis. Response to: â€˜MS score in systemic juvenile idiopathic arthritis: suitable for routine use?â€™ by Chi et al. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216067.	0.5	2
70	Acute pain management in children: a survey of Italian pediatricians. Italian Journal of Pediatrics, 2019, 45, 156.	1.0	8
71	Management of adult-onset Stillâ€™s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. Arthritis Research and Therapy, 2019, 21, 275.	1.6	20
72	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides â€“ the SHARE initiative. Rheumatology, 2019, 58, 656-671.	0.9	77

#	Article	IF	Citations
73	Muscle Expression of Type I and Type <scp>II</scp> Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. Arthritis and Rheumatology, 2019, 71, 1011-1021.	2.9	55
74	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. Journal of Rheumatology, 2019, 46, 190-197.	1.0	318
75	Criteria for Cytokine Storm Syndromes. , 2019, , 61-79.		0
76	Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. Clinical and Experimental Rheumatology, 2019, 37, 1084-1091.	0.4	2
77	American College of Rheumatology Provisional Criteria for Global Flares in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 813-822.	1.5	19
78	Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis. Current Rheumatology Reports, 2018, 20, 29.	2.1	6
79	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213030.	0.5	183
80	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	1.5	2
81	Measuring Disease Damage and Its Severity in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 1621-1629.	1.5	28
82	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. Arthritis Care and Research, 2018, 70, 1312-1319.	1.5	19
83	Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2018, 45, 3-5.	1.0	5
84	Preface. Rheumatology International, 2018, 38, 1-3.	1.5	6
85	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatology International, 2018, 38, 5-17.	1.5	74
86	Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213131.	0.5	119
87	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2018, 70, 409-419.	1.5	96
88	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.5	9
89	Type I interferon pathway activation in COPA syndrome. Clinical Immunology, 2018, 187, 33-36.	1.4	98
90	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Annals of the Rheumatic Diseases, 2018, 77, 241-250.	0.5	36

#	Article	IF	Citations
91	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.5	27
92	Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatric Rheumatology, 2018, 16, 46.	0.9	76
93	Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2018, 36, 1110-1116.	0.4	5
94	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet, The, 2017, 389, 909-916.	6.3	52
95	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.5	68
96	Elevated circulating levels of interferon-Î³ and interferon-Î³-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2017, 76, 166-172.	0.5	222
97	Consensus-based recommendations for the management of juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 329-340.	0.5	185
98	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1637-1641.	0.5	75
99	ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Annals of the Rheumatic Diseases, 2017, 76, 1648-1656.	0.5	199
100	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1788-1796.	0.5	139
101	Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Current Opinion in Rheumatology, 2017, 29, 523-529.	2.0	49
102	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	2.9	59
103	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	2.9	52
104	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 782-791.	0.5	51
105	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1965-1973.	0.5	105
106	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	0.9	50
107	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1884-1888.	1.0	11
108	What is the best definition of clinical remission in JIA?. Nature Reviews Rheumatology, 2017, 13, 460-461.	3.5	4

#	Article	IF	Citations
109	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2017, 69, 677-686.	1.5	52
110	Recent therapeutic advances in juvenile idiopathic arthritis. Best Practice and Research in Clinical Rheumatology, 2017, 31, 476-487.	1.4	9
111	Macrophage Activation Syndrome. , 2017, , 275-292.		0
112	Open issues in the assessment and management of pain in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 107, 123-126.	0.4	8
113	IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. Frontiers in Pharmacology, 2016, 7, 467.	1.6	39
114	The PRINTO juvenile dermatomyositis trial â€“ Authors' reply. Lancet, The, 2016, 387, 2601.	6.3	0
115	Delineating the Application of Ultrasound in Detecting Synovial Abnormalities of the Subtalar Joint in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2016, 68, 1346-1353.	1.5	22
116	A Metaâ€Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2016, 68, 1540-1550.	2.9	11
117	Unraveling the Phenotypic Variability of Juvenile Idiopathic Arthritis across Races or Geographic Areas â€" Key to Understanding Etiology and Genetic Factors?. Journal of Rheumatology, 2016, 43, 683-685.	1.0	15
118	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD Open, 2016, 2, e000302.	1.8	57
119	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatric Rheumatology, 2016, 14, 68.	0.9	35
120	Defining criteria for disease activity states in juvenile idiopathic arthritis: Table 1. Rheumatology, 2016, 55, 595-596.	0.9	22
121	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	2.9	427
122	Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatology and Therapy, 2016, 3, 187-207.	1.1	148
123	Clinical outcome measures in juvenile idiopathic arthritis. Pediatric Rheumatology, 2016, 14, 23.	0.9	133
124	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	1.8	57
125	Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases. Current Rheumatology Reports, 2016, 18, 8.	2.1	12
126	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.5	338

#	Article	IF	Citations
127	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, The, 2016, 387, 671-678.	6.3	168
128	Consequences and complications. , 2016, , 59-71.		1
129	General treatment aspects. , 2016, , 73-85.		1
130	Management of Patients with Juvenile Idiopathic Arthritis. , 2016, , 87-114.		2
131	Disease classification. , 2016, , 17-24.		0
132	Recurrent macrophage activation syndrome in spondyloarthritis and monoallelic missense mutations in PRF1: a description of one paediatric case. Clinical and Experimental Rheumatology, 2016, 34, 719.	0.4	5
133	Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clinical and Experimental Rheumatology, 2016, 34, 714-8.	0.4	11
134	Information technology in paediatric rheumatology. Clinical and Experimental Rheumatology, 2016, 34, S11-S16.	0.4	4
135	Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2015, 13, 55.	0.9	72
136	Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials, 2015, 16, 268.	0.7	17
137	Clinical features and correct diagnosis of macrophage activation syndrome. Expert Review of Clinical Immunology, 2015, 11, 1043-1053.	1.3	60
138	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 994-1001.	1.0	59
139	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. Autoimmunity Reviews, 2015, 14, 692-702.	2.5	63
140	Macrophage Activation Syndrome. Hematology/Oncology Clinics of North America, 2015, 29, 927-941.	0.9	121
141	Advances in biomarkers for paediatric rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 265-275.	3.5	37
142	Glucocorticoids in Juvenile Idiopathic Arthritis. NeuroImmunoModulation, 2015, 22, 112-118.	0.9	13
143	Evaluation of musculoskeletal complaints in children. , 2015, , 815-819.		0
144	The conundrum of juvenile psoriatic arthritis. Clinical and Experimental Rheumatology, 2015, 33, S40-3.	0.4	28

#	Article	IF	Citations
145	Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	0.9	0
146	Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Threeâ€Variable Juvenile Arthritis Disease Activity Score. Arthritis Care and Research, 2014, 66, 1703-1709.	1.5	115
147	CACP syndrome: identification of five novel mutations and of the first case of UPD in the largest European cohort. European Journal of Human Genetics, 2014, 22, 197-201.	1.4	25
148	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2â€Year Results From the TENDER Trial. Arthritis and Rheumatology, 2014, 66, S96.	2.9	2
149	A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab. Arthritis and Rheumatology, 2014, 66, S83.	2.9	14
150	Frequency of Radiographic Damage and Progression in Individual Joints in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 27-33.	1.5	9
151	Agreement Among Musculoskeletal Pediatric Specialists in the Assessment of Radiographic Joint Damage in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 34-39.	1.5	3
152	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. Arthritis and Rheumatology, 2014, 66, S17-S18.	2.9	4
153	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. Pediatric Rheumatology, 2014, 12, 49.	0.9	6
154	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	0.9	6
155	Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	0.9	0
156	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. Pediatric Rheumatology, 2014, 12, .	0.9	0
157	Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Pediatric Rheumatology, 2014, 12, .	0.9	5
158	The Functional Significance of Common Polymorphisms in Zinc Finger Transcription Factors. G3: Genes, Genomes, Genetics, 2014, 4, 1647-1655.	0.8	9
159	Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2014, 73, 1083-1090.	0.5	113
160	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	2.9	322
161	A30: Assessment of Construct and Discriminative Validity of the 3-Variable JADAS in Relation of Parent-Reported Outcomes. Arthritis and Rheumatology, 2014, 66, S46-S46.	2.9	1
162	Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. Annals of the Rheumatic Diseases, 2014, 73, 1380-1383.	0.5	77

#	Article	IF	Citations
163	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 2871-2880.	2.9	101
164	Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. Pediatric Rheumatology, 2014, 12, 31.	0.9	9
165	Female Sex and Oligoarthritis Category Are Not Risk Factors for Uveitis in Italian Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 1416-1425.	1.0	25
166	Treating Juvenile Idiopathic Arthritis According to JADAS-Based Targets. Annals of Paediatric Rheumatology, 2014, 3, 4.	0.0	8
167	Evaluation of Biopsychosocial Aspects of Patients with Juvenile Autoinflammatory Disease: A Qualitative Study. Annals of Paediatric Rheumatology, 2014, 3, 62.	0.0	4
168	The invisible part of the iceberg: qualitative aspects of childhood vasculitis. Clinical and Experimental Rheumatology, 2014, 32, S122-7.	0.4	4
169	Periostin gene variants are associated with disease course and severity in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2014, 32, 747-53.	0.4	3
170	MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2013, 72, 363-368.	0.5	36
171	Delineating the Role of Multiple Intraarticular Corticosteroid Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era. Arthritis Care and Research, 2013, 65, 1112-1120.	1.5	38
172	Methotrexate Therapy May Prevent the Onset of Uveitis in Juvenile Idiopathic Arthritis. Journal of Pediatrics, 2013, 163, 879-884.	0.9	54
173	Juvenile idiopathic arthritisâ€"are biologic agents effective for pain?. Nature Reviews Rheumatology, 2013, 9, 447-448.	3.5	12
174	Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept. Journal of Rheumatology, 2013, 40, 192-200.	1.0	43
175	Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. Annals of the Rheumatic Diseases, 2013, 72, 223-228.	0.5	85
176	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2013, 72, 686-693.	0.5	109
177	It Is Worth Including Assessment of Disease Activity State in Juvenile Arthritis Clinical Trials. Arthritis Care and Research, 2013, 65, 1207-1210.	1.5	9
178	Towards a role of ultrasound in children with juvenile idiopathic arthritis. Rheumatology, 2013, 52, 413-420.	0.9	43
179	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Annals of the Rheumatic Diseases, 2013, 72, 1503-1509.	0.5	12
180	Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. Clinical and Experimental Rheumatology, 2013, 31, 964-8.	0.4	8

#	Article	IF	Citations
181	A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, 511-517.	0.5	55
182	Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2012, 39, 856-863.	1.0	72
183	Macrophage activation syndrome. Indian Journal of Rheumatology, 2012, 7, 27-35.	0.2	6
184	Novel automated system for magnetic resonance imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. Arthritis Care and Research, 2012, 64, 1657-1664.	1.5	15
185	Advances and challenges in imaging in juvenile idiopathic arthritis. Nature Reviews Rheumatology, 2012, 8, 329-336.	3.5	73
186	Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. Pediatric Rheumatology, 2012, 10, 39.	0.9	70
187	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2385-2395.	13.9	716
188	Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes and Immunity, 2012, 13, 289-298.	2.2	318
189	Inactive disease and remission in childhoodâ€onset systemic lupus erythematosus. Arthritis Care and Research, 2012, 64, 683-693.	1.5	34
190	Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis and Rheumatism, 2012, 64, 2366-2374.	6.7	171
191	Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis?. Arthritis and Rheumatism, 2012, 64, 33-36.	6.7	6
192	A phase II, multicenter, openâ€label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and Rheumatism, 2012, 64, 557-567.	6.7	167
193	Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Annals of Paediatric Rheumatology, 2012, 1, 1.	0.0	15
194	Recent advances in quantitative assessment of juvenile idiopathic arthritis. Annals of Paediatric Rheumatology, 2012, 1, 84.	0.0	7
195	Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clinical and Experimental Rheumatology, 2012, 30, S162-8.	0.4	13
196	Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2012, 30, S157-62.	0.4	34
197	Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 440-446.	0.5	60
198	An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2011, 38, 764-768.	1.0	140

#	Article	IF	Citations
199	Vaccination in paediatric patients with auto-immune rheumatic diseases: A systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmunity Reviews, 2011, 11, 112-122.	2.5	57
200	Criteria to define response to therapy in paediatric rheumatic diseases. European Journal of Clinical Pharmacology, 2011, 67, 125-131.	0.8	24
201	Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2011, 9, .	0.9	0
202	Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2011, 9, .	0.9	2
203	Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM). Pediatric Rheumatology, 2011, 9, P51.	0.9	0
204	Preliminary criteria for global flares in childhoodâ€•onset systemic lupus erythematosus. Arthritis Care and Research, 2011, 63, 1213-1223.	1.5	28
205	Development and initial validation of composite parentâ€•and childâ€•centered disease assessment indices for juvenile idiopathic arthritis. Arthritis Care and Research, 2011, 63, 1262-1270.	1.5	27
206	Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care and Research, 2011, 63, S112-7.	1.5	55
207	Antinuclear antibodyâ€“positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis and Rheumatism, 2011, 63, 267-275.	6.7	140
208	Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: An international multicenter PRINTO study. Arthritis and Rheumatism, 2011, 63, 3142-3152.	6.7	47
209	Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 1627-1634.	0.9	59
210	A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report. Journal of Rheumatology, 2011, 38, 938-953.	1.0	159
211	EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2011, 70, 1704-1712.	0.5	193
212	Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clinical and Experimental Rheumatology, 2011, 29, 117-24.	0.4	34
213	Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2010, 37, 1534-1541.	1.0	119
214	Longâ€•term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care and Research, 2010, 62, 63-72.	1.5	207
215	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	1.5	84
216	Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission<subtitle>A Randomized Clinical Trial</subtitle>. JAMA - Journal of the American Medical Association, 2010, 303, 1266.	3.8	229

#	Article	IF	Citations
217	Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index?. Annals of the Rheumatic Diseases, 2010, 69, 82-87.	0.5	11
218	Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Annals of the Rheumatic Diseases, 2010, 69, 1479-1483.	0.5	46
219	Development and Initial Validation of a Radiographic Scoring System for the Hip in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2010, 37, 432-439.	1.0	35
220	Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology, 2010, 49, 441-449.	0.9	202
221	A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. Rheumatology, 2010, 49, 1272-1280.	0.9	39
222	Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. Rheumatology, 2010, 49, 178-185.	0.9	69
223	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 2010, 69, 790-797.	0.5	187
224	Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. Clinical and Experimental Rheumatology, 2010, 28, 424-33.	0.4	3
225	Factors affecting survival in juvenile systemic sclerosis. Rheumatology, 2009, 48, 119-122.	0.9	71
226	Achievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 628-634.	1.0	61
227	Developing outcome measures for paediatric rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2009, 23, 609-624.	1.4	47
228	Healthâ€related quality of life of patients with juvenile dermatomyositis: Results from the paediatric rheumatology international trials organisation multinational quality of life cohort study. Arthritis and Rheumatism, 2009, 61, 509-517.	6.7	45
229	Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis and Rheumatism, 2009, 61, 658-666.	6.7	579
230	Comparison of clinical versus ultrasoundâ€determined synovitis in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2009, 61, 1497-1504.	6.7	156
231	Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirtyâ€eight patients. Arthritis and Rheumatism, 2009, 60, 3388-3399.	6.7	231
232	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis and Rheumatism, 2009, 60, 3425-3435.	6.7	107
233	HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatric Pulmonology, 2009, 44, 1226-1234.	1.0	22
234	The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus, 2009, 18, 894-899.	0.8	54

#	Article	IF	Citations
235	Development and Testing of Reduced Joint Counts in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 183-190.	1.0	40
236	Consensus procedures and their role in pediatric rheumatology. Current Rheumatology Reports, 2008, 10, 142-146.	2.1	44
237	The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/european League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study. Arthritis and Rheumatism, 2008, 59, 4-13.	6.7	136
238	The pattern of response to antiâ€“interleukinâ€1 treatment distinguishes two subsets of patients with systemicâ€onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 58, 1505-1515.	6.7	346
239	Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 59, 1112-1119.	6.7	33
240	Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 59, 1120-1127.	6.7	98
241	Assessing current outcomes of juvenile idiopathic arthritis: A crossâ€sectional study in a tertiary center sample. Arthritis and Rheumatism, 2008, 59, 1571-1579.	6.7	52
242	Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 59, 1764-1772.	6.7	126
243	Treatment of Takayasu's Arteritis with Tumor Necrosis Factor Antagonists. Journal of Pediatrics, 2008, 153, 432-434.	0.9	49
244	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. Pediatrics, 2008, 122, e1100-e1107.	1.0	193
245	A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2008, 67, 1159-1164.	0.5	34
246	The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials. Journal of Rheumatology, 2008, 35, 553-7.	1.0	25
247	The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2007, 67, 370-374.	0.5	67
248	Chapter 4 Macrophage Activation Syndrome. Handbook of Systemic Autoimmune Diseases, 2007, , 55-275.	0.1	1
249	Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2007, 67, 309-314.	0.5	55
250	Review: The Paediatric Rheumatology International Trials Organization (PRINTO). Lupus, 2007, 16, 670-676.	0.8	23
251	Macrophage Activation Syndrome in Childhood Rheumatic Diseases. Current Rheumatology Reviews, 2007, 3, 225-230.	0.4	1
252	Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis. Rheumatology, 2007, 46, 141-145.	0.9	37

#	Article	IF	Citations
253	Juvenile idiopathic arthritis. Lancet, The, 2007, 369, 767-778.	6.3	1,426
254	Review: Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?. Lupus, 2007, 16, 587-592.	0.8	63
255	Antiphospholipid Syndrome in Pediatrics. Rheumatic Disease Clinics of North America, 2007, 33, 499-523.	0.8	32
256	Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study. Arthritis and Rheumatism, 2007, 57, 35-43.	6.7	121
257	The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis and Rheumatism, 2007, 57, 203-212.	6.7	164
258	Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 56, 3087-3095.	6.7	80
259	A randomized, placeboâ€controlled trial of infliximab plus methotrexate for the treatment of polyarticularâ€course juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 3096-3106.	6.7	373
260	Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 57, 913-920.	6.7	95
261	Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2007, 5, 23.	0.9	14
262	Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. Journal of Rheumatology, 2007, 34, 1773-6.	1.0	30
263	Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2006, 55, 177-183.	6.7	70
264	The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement. Arthritis and Rheumatism, 2006, 55, 355-363.	6.7	72
265	A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 2989-2996.	6.7	133
266	Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database. Arthritis and Rheumatism, 2006, 54, 3971-3978.	6.7	189
267	Use of the sharp and larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2006, 55, 717-723.	6.7	61
268	Reply to letter by Isenberg and Gordon commenting on the Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 3723-3724.	6.7	1
269	Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. Arthritis and Rheumatism, 2006, 55, 843-849.	6.7	44
270	Clinical assessment in juvenile dermatomyositis. Autoimmunity, 2006, 39, 197-203.	1.2	22

#	Article	IF	Citations
271	Weighting improves the information provided by joint counts on the severity of arthritis and its impact on patientsâ€™ well-being in juvenile idiopathic arthritis. Rheumatology, 2006, 45, 343-347.	0.9	8
272	Relationship between Damage Accrual, Disease Flares and Cumulative Drug Therapies in Juvenile-Onset Systemic Lupus Erythematosus. Lupus, 2006, 15, 515-520.	0.8	75
273	Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. Journal of Rheumatology, 2006, 33, 789-95.	1.0	44
274	Outcome in juvenile onset systemic lupus erythematosus. Current Opinion in Rheumatology, 2005, 17, 568-573.	2.0	77
275	Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis and Rheumatism, 2005, 52, 826-832.	6.7	197
276	Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2005, 52, 2092-2102.	6.7	142
277	The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. Arthritis and Rheumatism, 2005, 52, 2854-2864.	6.7	77
278	Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis and Rheumatism, 2005, 52, 3554-3562.	6.7	200
279	EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Annals of the Rheumatic Diseases, 2005, 65, 936-941.	0.5	659
280	Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2005, 64, 257-261.	0.5	35
281	The Long-Term Outcome of Juvenile Idiopathic Arthritis. Current Rheumatology Reviews, 2005, 1, 151-155.	0.4	2
282	Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Journal of Pediatrics, 2005, 146, 598-604.	0.9	365
283	Antiphospholipid Syndrome. Pediatric Clinics of North America, 2005, 52, 469-491.	0.9	42
284	Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. Journal of Rheumatology, 2005, 32, 1805-10.	1.0	28
285	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology, 2004, 43, 49-54.	0.9	311
286	Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis and Rheumatism, 2004, 51, 458-464.	6.7	93
287	Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. Journal of Rheumatology, 2004, 31, 795-800.	1.0	28
288	Functional and prognostic relevance of the ?173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 1398-1407.	6.7	173

#	Article	IF	Citations
289	Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. Arthritis and Rheumatism, 2003, 49, 488-493.	6.7	27
290	Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis and Rheumatism, 2003, 49, 501-507.	6.7	150
291	Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 3509-3517.	6.7	93
292	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. British Journal of Rheumatology, 2003, 42, 1452-1459.	2.5	209
293	Outcome of primary antiphospholipid syndrome in childhood. Lupus, 2003, 12, 449-453.	0.8	63
294	Uncommon Syndromes and Treatment Manifestations of Malignancy. Journal of Clinical Oncology, 2003, 21, 172-173.	0.8	13
295	Macrophage activation syndrome. Current Opinion in Rheumatology, 2002, 14, 548-552.	2.0	258
296	Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 232-237.	6.7	67
297	Self epitopes shared between human skeletal myosin andStreptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis and Rheumatism, 2002, 46, 3015-3025.	6.7	55
298	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 246-7.	0.7	4
299	Nephroticâ€range proteinuria, the major risk factor for early atherosclerosis in juvenileâ€onset systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 1405-1409.	6.7	103
300	Juvenile Idiopathic Arthritis. BioDrugs, 2000, 14, 93-98.	2.2	15
301	Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. British Journal of Rheumatology, 1999, 38, 176-180.	2.5	34
302	Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. Rheumatology, 1999, 38, 773-773.	0.9	17
303	Wegener Granulomatosis in a Child: Cutaneous Findings as the Presentingâ€ƒ Signs. Pediatric Dermatology, 1999, 16, 277-280.	0.5	19
304	Aortic valve regurgitation as the presenting sign of Takayasu arteritis. European Journal of Pediatrics, 1999, 158, 281-283.	1.3	13
305	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 807-811.	6.7	71
306	The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. Journal of Pediatrics, 1999, 135, 316-320.	0.9	57

#	Article	IF	Citations
307	Wegener's granulomatosis presenting with life-threatening pulmonary hemorrhage in a boy with type 1 diabetes. Diabetes Care, 1999, 22, 1591-1592.	4.3	4
308	Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. Journal of Pediatrics, 1998, 133, 262-265.	0.9	58
309	Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Annals of the Rheumatic Diseases, 1998, 57, 38-41.	0.5	84
310	Correlation between conventional disease activity measures in juvenile chronic arthritis. Annals of the Rheumatic Diseases, 1997, 56, 197-200.	0.5	83
311	Cytokines in juvenile rheumatoid arthritis. Current Opinion in Rheumatology, 1997, 9, 428-433.	2.0	44
312	The Clinical Significance of Antiphospholipid Antibodies. Annals of Medicine, 1997, 29, 159-163.	1.5	27
313	ANTIPHOSPHOLIPID ANTIBODY SYNDROME IN PEDIATRIC PATIENTS. Rheumatic Disease Clinics of North America, 1997, 23, 657-676.	0.8	70
314	Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism, 1997, 40, 1202-1209.	6.7	40
315	Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism, 1997, 40, 1202-1209.	6.7	922
316	Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. Journal of Pediatrics, 1996, 128, 275-278.	0.9	134
317	IgA Nephropathy and Henoch-SchÃ¶nlein Syndrome Occurring in the Same Patient. Nephron, 1996, 72, 111-112.	0.9	18
318	Pulmonary function in children with systemic lupus erythematosus.. Thorax, 1996, 51, 424-428.	2.7	15
319	Neurological Disorders, other than Stroke, Associated with Antiphospholipid Antibodies in Childhood. Neuropediatrics, 1996, 27, 149-153.	0.3	63
320	Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis. Clinical Rheumatology, 1995, 14, 322-326.	1.0	24
321	Frequency and complications of chronic iridocyclitis in ANA-positive pauciarticular juvenile chronic arthritis. International Ophthalmology, 1995, 18, 225-228.	0.6	11
322	Anticardiolipin Antibodies in Pediatric Systemic Lupus Erythematosus. JAMA Pediatrics, 1994, 148, 398.	3.6	71
323	Antiphospholipid antibodies in paediatrics. European Journal of Pediatrics, 1994, 153, 472-479.	1.3	31
324	Antiphospholipid antibodies in children with idiopathic cerebral ischaemia. Lancet, The, 1994, 344, 1232.	6.3	9

#	Article	IF	Citations
325	Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet, The, 1994, 344, 1052-1054.	6.3	63
326	Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations. Journal of Pediatrics, 1994, 124, 742-744.	0.9	56
327	Antiphospholipid antibody syndrome as a cause of venous thrombosis in childhood. Journal of Pediatrics, 1994, 124, 831-832.	0.9	9
328	Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. Journal of Pediatrics, 1994, 124, 561-565.	0.9	52
329	Chronic intoxication by ethane-1-hydroxy-1,1-diphosphonate (EHDP) in a child with myositis ossificans progressiva. Pediatric Radiology, 1993, 23, 459-462.	1.1	7
330	Anti-DNA Antibodies in the Primary Antiphospholipid Syndrome. Rheumatology, 1993, 32, 1028-1028.	0.9	4
331	Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis.. Archives of Disease in Childhood, 1992, 67, 1384-1385.	1.0	33
332	Recurrent juvenile dermatomyositis and cutaneous necrotizing arteritis with molecular mimicry between streptococcal type 5 M protein and human skeletal myosin. Journal of Pediatrics, 1992, 121, 739-742.	0.9	35
333	Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis. Journal of Pediatrics, 1991, 119, 333-334.	0.9	14
334	Correlation of Serum Interleukin-6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rheumatoid Arthritis. Arthritis and Rheumatism, 1991, 34, 1158-1163.	6.7	325
335	Prevalence of anticardiolipin antibodies in juvenile chronic arthritis.. Annals of the Rheumatic Diseases, 1991, 50, 599-601.	0.5	51
336	Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis.. Annals of the Rheumatic Diseases, 1989, 48, 582-585.	0.5	2
337	Frequency of Autoantibodies in Normal Children. JAMA Pediatrics, 1989, 143, 493.	3.6	15
338	Systemic Vasculitis Followed by Chronic Myelogenous Leukemia. Pediatric Hematology and Oncology, 1988, 5, 315-318.	0.3	0
339	Systemic lupus erythematosus with jaccoud's arthropathy mimicking juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1987, 30, 1062-1064.	6.7	29
340	Urinary microscopy in the diagnosis of haematuria in schï¿½nlein-henoch purpura. European Journal of Pediatrics, 1986, 144, 591-593.	1.3	6
341	IgG subclass serum levels in juvenile chronic arthritis.. Annals of the Rheumatic Diseases, 1986, 45, 400-404.	0.5	9
342	Henoch-Schonlein syndrome and selective IgA deficiency.. Archives of Disease in Childhood, 1985, 60, 160-162.	1.0	12